Feryal Clark MP: speeches

Speeches

• 16 Jun 2025 · Animal Experiments: Medical Research · Hansard source

  More

  The road map will set out how we can get to a place where we can phase out animal testing. I cannot set out dates and what the road map will include, but a huge amount of investment is going into many of the projects that have been mentioned—hopefully that will all be included in the road map. As colleagues have said, where other nations are developing new ways to phase out animal testing, we will look into those and see where we can replicate them. We are closely following developments in Europe and the US, and we work closely with both the Food and Drug Administration and our European colleagues on this matter. Currently, the Government support the development and dissemination of the three Rs through UK Research and Innovation. That is primarily achieved through funding of the NC3Rs, which works nationally and internationally to drive the uptake of alternative technologies and to ensure that advances are reflected in policy, practice and regulation on animal testing. Since its launch in 2004, it has committed over £100 million through its research, innovation and early career awards to provide new three Rs approaches for scientists in academia and industry to use. That is only part of our support. Many UKRI programmes, including research on organoids, cell behaviour and AI, may eventually lead to the development of non-animal testing methods, but they are not categorised as such because they are basic research at the moment. The Government have also provided more than £6 million of funding for seven centres of excellence for regulatory science and innovation to help drive advancement in healthcare. The in-silico CERSI, led by the University of Manchester, aims to support the use of computational techniques to test and develop medical products. To be clear, we want to replace the use of animals in scientific procedures with alternatives where we can, but for now the carefully regulated use of animals in scientific research remains necessary if we are to protect humans and the wider environment. I thank hon. Members once again for their insightful contributions to the debate. I look forward to us working together going forward. Question put and agreed to.

• 16 Jun 2025 · Animal Experiments: Medical Research · Hansard source

  More

  I thank my hon. Friend the Member for North Ayrshire and Arran (Irene Campbell) for opening this important debate, and I thank all hon. Members for their contributions. We appreciate that the use of animals in medical research stirs the strong emotional instincts of many people across the UK, including many colleagues here. The day when we can finally bring an end to animal testing cannot come soon enough. Sadly, however, that day is not here yet. Phasing out animal testing has to be done in lockstep with the development of safe, accurate and validated alternatives. The reality is that the technology is not yet advanced enough for alternative methods to completely replace the use of animals. Consequently, the carefully regulated use of animals remains necessary to protect humans and the wider environment. Animal testing continues to be required by international agreements, which all global medicines regulators follow, including the UK’s Medicines and Healthcare products Regulatory Agency. Such testing is regulated through the Animals (Scientific Procedures) Act 1986, known as ASPA. The Act specifies that animals can only be used in science for specific, limited purposes where there are no alternatives, where the number of animals used is the minimum needed to achieve the scientific benefit, and where the potential harm to the animals is limited to the absolute minimum. This is known as the three Rs: replacement, reduction and refinement. The system also includes a three-tier system of licensing that licenses each establishment, project and individual involved in performing regulated procedures involving animals. New technologies including AI, as referred to by colleagues, do offer potentially revolutionary ways to create alternative technologies. That is why our manifesto commits us to partnering with scientists, industry and civil society as we work towards the phasing out of animal testing. As the first step, we will publish a strategy later this year laying out how the Government will support the development, validation and uptake of alternative methods, and officials are working on this as we speak. The strategy will set out how we will create a research and innovation system that replaces animals with alternative methods wherever possible and that places the UK at the forefront of international efforts to drive this agenda. I am proud to say that the UK is already world-leading in the development of alternative methods, and we are keen to utilise this technology as much as possible.

• 14 May 2025 · Artificial Intelligence: Environmental Impact · Hansard source

  More

  DSIT works closely with other Departments, including the Department for Energy Security and Net Zero and the Department for Environment, Food and Rural Affairs, to align AI energy demand with future energy planning to ensure long-term sustainability. We understand that AI is an energy-hungry technology, which is why we have set up the AI energy council. Through that council, we are assessing ways to address the growing energy demands of AI and AI sustainability, including by exploring bold clean energy solutions, from next generation renewables to small modular reactors.

• 14 May 2025 · Artificial Intelligence: Environmental Impact · Hansard source

  More

  I assure my hon. Friend that the Government are committed to ensuring that AI development aligns with sustainability goals. We welcome the advances in cooling technologies, such as dry cooling and closed-loop systems, in addition to promoting the use of renewable energy resources. I chair the AI Ministers group, which brings together Ministers from all Departments to co-ordinate cross-cutting challenges, including water consumption.

• 24 Mar 2025 · BioNTech UK: Financial Assistance · Hansard source

  More

  I beg to move, That this House authorises the Secretary of State to undertake to pay, and to pay by way of financial assistance under section 8 of the Industrial Development Act 1982, a grant or grants exceeding £30 million and up to a total of £129 million to BioNTech UK Limited to support their planned expansion of research and development and artificial intelligence activities in the UK over the next 10 years. It is an honour to serve under your chairmanship, Ms Jardine. This investment comes at an important time for the UK’s thriving life sciences sector, which forms a key pillar of two of the Government’s missions: to kick-start economic growth; and to build an NHS fit for the future. The sector is responsible for over £100 billion of turnover in the UK, and it supports over 304,000 jobs in 6,850 businesses. In addition to supporting our economy, the sector also delivers for patients by providing the medicines and technologies that people need to live longer, healthier lives. As we will set out in the life sciences sector plan, we must build on our world-leading R&D ecosystem and double down on rebuilding an internationally competitive business environment so that innovative companies can start, scale and stay here in the UK. To deliver that plan, we will continue to work in partnership with industry, our life sciences ecosystem and the NHS to seize opportunities that will foster innovation across the UK. To that end, through this proposed grant, we have an opportunity for the UK to secure international investment in innovative, cutting-edge R&D in the face of increasing global competition. As the right hon. and hon. Members present know, BioNTech is an international leader in the biotechnology industry, and the developer of the first licensed mRNA covid-19 vaccine. Building on the vaccine’s success and global impact, BioNTech has applied for a Government grant of £129 million to support its transformation and UK expansion, which will see it invest circa £1 billion over 10 years. Supported by the grant, BioNTech research activities will focus on structural biology, regenerative medicine, oncology and AI-driven drug discovery, spanning three locations and creating about 460 new, directly-employed, highly skilled jobs. In Cambridge, BioNTech will set up a new centre of excellence to focus on drug discovery and development of new treatments for cancer and other serious diseases. That directly supports the Government’s ambition to boost the Oxford-Cambridge growth corridor. In London, BioNTech intends to establish a major hub, including a centre of AI expertise to leverage this game-changing technology and to enhance our understanding of diseases, their causes and drug targeting. At a third site—to be announced shortly—BioNTech plans to undertake R&D into vaccines, including for diseases with high pandemic potential. BioNTech’s decision to invest in the UK and to expand its R&D activities builds on the Government’s existing strategic partnership with the company. That includes BioNTech’s work to provide up to 10,000 NHS patients with personalised immunotherapies by 2030, which is already transforming health outcomes by enabling UK patients to be among the first in the world to benefit from cancer vaccines. That support for BioNTech is further evidence of the Government’s backing of a world-leading life sciences sector. Working together, we are driving growth, creating jobs and fostering innovation that will translate into positive outcomes for patients. Supporting BioNTech’s investment is another signal of our commitment to this crucial sector ahead of launching our ambitious life sciences sector plan in the spring. I commend the motion to the Committee.

• 24 Mar 2025 · BioNTech UK: Financial Assistance · Hansard source

  More

  I thank the Opposition and Liberal Democrat spokespeople. The funding we have discussed today will unlock around £1 billion to further boost the UK’s life sciences sector and, in turn, support the Government’s missions to kick-start economic growth and build an NHS fit for the future. It will also build on our significant progress and commitments to date, including the life sciences innovative manufacturing fund of up to £520 million announced by the Chancellor in October 2024, and our landmark partnerships with Oxford Nanopore and Eli Lilly. The hon. Member for Runnymede and Weybridge (Dr Spencer) commented on the investment environment. I am sure he did not miss the fact that this Government attracted £63 billion-worth of investment at the last international investment summit. We have done the hard work to make that investment a reality. He may be interested to hear that, according to the latest CEO survey by PricewaterhouseCoopers, the UK is the second best country in the world in which to invest. However, we are not complacent, and we are fully committed to making the UK the best place to invest. The life sciences are an area of huge UK expertise, and they are key to that commitment. Securing this investment will send a clear message to innovative companies that the UK is open for business. The hon. Member for Harpenden and Berkhamsted (Victoria Collins) asked about monitoring. The financial assistance will be monitored through the normal procedures used for any investment made by the Government. I am happy to send her details of that process and the timeline for this investment. Working together with industry, this Government are delivering better patient outcomes and driving economic growth. I look forward to continuing that work, and to building on that momentum through the publication and rapid delivery of the life sciences sector plan and industrial strategy in the spring. I commend the motion to the Committee. Question put and agreed to .

• 26 Feb 2025 · Online Safety Act: Implementation · Hansard source

  More

  Ofcom has had to spend a long time consulting on the codes to ensure that they are as proofed against judicial review as possible. Any re-consultation or review of the codes will result in a delay, and the best way to ensure that we can protect children is to implement the Act as soon as possible. My hon. Friend referred to the fact that both Ofcom and the Secretary of State have said that this is not a done deal; it is an iterative process, so of course we expect those codes to be reviewed. As I said, Ofcom is moving forward with implementation of the Act. In a matter of weeks we will start to see, for the first time, safety duties making a material difference to online experiences for adults and children. Platforms are already duty-bound to assess the risk of illegal content and, with a deadline of 16 March, to complete risk assessments. Once legal harm codes come into effect from 17 March, Ofcom will be able to enforce legal safety duties. Shortly following that in April, Ofcom will publish the child safety codes and associated guidance, starting the clock for services to assess the risk of content harmful to children on their platforms. The child safety duties should be fully in effect by the summer. My hon. Friend the Member for Darlington also raised the issue of dynamic risk assessment. I understand that she is in conversation with Ofcom and Ministers on that. I will await the outcome of those discussions. The implementation of the Act will bring in long overdue measures, such as preventing children from accessing pornography and legal content encouraging suicide, self-harm or eating disorders. I have heard concerns raised by hon. Members regarding Ofcom’s approach, particularly to harmful functionalities and safety by design. We understand there is still a lot of work to be done, which is why the Secretary of State’s statement of strategic priorities places a high importance on safety by design. However, it is important not to lose sight of the positive steps we expect to see this year under the Act. For instance, Ofcom’s draft child codes already include specific measures to address harmful algorithms, among other safety recommendations. We expect Ofcom will continue to build on those important measures in the codes. Questions were asked about whether the Government have plans to water down the Act. I can categorically state that there are no plans to water down the measures. The Secretary of State has made it very clear that any social media company that wants to operate in our society will have to comply with the law of the land. Whatever changes are made in other jurisdictions, the law of the land will remain.

• 8 Jan 2025 · Innovation: Staffordshire · Hansard source

  More

  In case the House has not heard, this Government are driving innovation, with a record £20.4 billion of research and development investment for 2025-26, powering an innovation-led economy across the UK. In Staffordshire, UK Research and Innovation is backing more than £29 million for 70 cutting-edge research and innovation projects. A stand-out example is Innovate UK’s support for the Staffordshire net zero skills for growth project, which is equipping the country to seize opportunities in the net zero transition.